Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

996 - The impact of continuing ALK inhibitors beyond initial disease progression on clinical outcome in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter retrospective analysis

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Shinya Sakata

Citation

Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425

Authors

S. Sakata1, S. Saeki1, Y. Sakata2, K. Kawamura2, K. Ichikado2, M. Inaba3, S. Ushijima3, K. Imamura4, K. Iyonaga4, T. Kumabe5, R. Fujita5, K. Kashiwabara6, S. Fujii6, T. Komatsu7, O. Sakamoto7, H. Okabayashi8, K. Saruwatari1, Y. Tomita1, T. Sakagami1

Author affiliations

  • 1 Respiratory Medicine, Kumamoto University Hospital, 860-8556 - Kumamoto city/JP
  • 2 Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto city/JP
  • 3 Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto city/JP
  • 4 Respiratory Medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto city/JP
  • 5 Internal Medicine, Miyazaki prefectural Nobeoka Hospital, Nobeoka/JP
  • 6 Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto city/JP
  • 7 Respiratory Medicine, Kumamoto Saishunso Hospital, Kumamoto city/JP
  • 8 Respiratory Medicine, Omuta Tenryo Hospital, Omuta/JP
More

Resources

Abstract 996

Background

The efficacy of continuing anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) beyond initial disease progression for ALK-positive patients with advanced non-small cell lung cancer (NSCLC) has not been fully understood.

Methods

We retrospectively analyzed 74 ALK-positive advanced NSCLC patients who received ALK-TKIs between August 2011 and July 2017 in Kumamoto university hospital and community hospitals in Japan. Continuation of ALK-TKIs beyond progressive disease (PD) was defined as > 3 weeks of ALK-TKIs treatment after PD confirmation.

Results

Among 74 patients, 32 received alectinib treatment and 42 received crizotinib as first ALK-TKI treatments. Progression free survival of patients with alectinib was significantly longer than that of crizotinib in the ALK inhibitor-naïve population (32.8 months versus 13.3 months, P = 0.005). Forty-one patients among the 74 patients treated with ALK-TKIs had RECIST-defined PD. Eleven of 41 RECIST-defined PD patients continued ALK-TKI therapy. The median time to tumor progression of these 11 patients was 11.7 months. The median overall survival of patients with or without continuation of ALK-TKIs beyond initial PD was 59.7 months versus 51.2 months, respectively (P = 0.35).

Conclusions

Continuing ALK inhibition with crizotinib or alectinib after initial PD may provide survival benefit to patients with advanced ALK-positive NSCLC.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Shinya Sakata.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.